Humira exclusivity expires in 2023: Will biosimilar boom benefit patients or industry?

In 2021, Humira — the blockbuster biologic that has for years been the highest grossing drug in the world — accomplished something that no drug had previously achieved when its global revenues topped $20 billion.More precisely, Humira (adalimumab) earned $20.7 billion in revenue in 2021 — including $17.3 billion just from U.S. sales — for its manufacturer AbbVie after coming just a few hundred million short of the $20 billion benchmark for three years in a row. However, while this news was no-doubt greeted warmly by the company, AbbVie’s fourth-quarter 2021Read More